×
ADVERTISEMENT

MARCH 22, 2024

FDA Approves Duvyzat for DMD


Originally published by our sister publication Specialty Pharmacy Continuum

By SPC Staff

The FDA approved givinostat (Duvyzat, Italfarmaco S.p.A.) oral medication for Duchenne muscular dystrophy (DMD) in patients aged 6 years of age and older. 

Givinostat is the first nonsteroidal drug to treat patients with all genetic variants of the disease, the agency noted. The drug is a histone deacetylase inhibitor that reduces inflammation and loss of muscle. 

The approval was based on data from a